

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Erik Buntinx
Serial No. : 10/725,965
Filed : December 2, 2003
For : METHOD OF TREATING MENTAL DISORDERS USING OF D4
AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR
PARTIAL AGONISTS
Art Unit : 1627
Examiner : Umamaheswari Ramachandran
Customer No. : 1912
Confirmation No.: 2844

COMMUNICATION AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A Notice of Allowance was issued on August 10, 2010 in connection with the above-identified application. The Fees Transmittal Form PTOL-85 and fee payment are due November 10, 2010 and have not been submitted. Accordingly, this Request for Continued Examination (RCE) and Supplemental Information Disclosure Statement (SIDS) are being timely filed. Authorization is hereby given to charge the \$405.00 fee for a Request for Continued Examination for a small entity to Deposit Account No. 01-1785.

EFS
Confirmation No. 2844
Appl. No. 10/725,965

Dkt. No. 29248/18

Supplemental Information Disclosure Statement

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the references that are listed on the attached form PTO/SB/08A (5 pages). Copies of the non patent literature documents are also attached.

Authorization is hereby given to charge the \$405.00 fee for a Request for Continued Examination and any required additional fee for a small entity to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: September 27, 2010
New York, New York

By Alan D. Miller/
Alan D. Miller, Reg. No. 42,889